SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir Biotechnology's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc. 舊金山--(美國商業資訊)--Vir Biotechnology Inc.(納斯達克股票代碼:VIR)今天宣佈,Marianne De Backervan.Sc. 博士、工商管理碩士、首席執行官定於太平洋時間12月3日星期二上午6點10分/美國東部時間上午9點10分在佛羅里達州邁阿密舉行的第七屆Evercore ISI HealthConx年度會議的爐邊談話。
爐邊談話的網絡直播將在Vir Biotechnology網站投資者欄目的 「活動與演示」 下提供,並將在那裏存檔30天。
關於 Vir 生物技術有限公司
Vir Biotechnology, Inc. 是一家處於臨床階段的生物製藥公司,致力於通過發現和開發治療嚴重傳染病和癌症的藥物來推動免疫系統改變生活。Vir Biotechnology的臨床階段產品組合包括針對慢性三角型肝炎和慢性乙型肝炎感染的傳染病項目,以及針對實體瘤適應症中多個經過臨床驗證的靶標的項目。Vir Biotechnology還擁有涵蓋一系列傳染病和腫瘤惡性腫瘤的臨床前項目組合。Vir Biotechnology經常在其網站上發佈可能對投資者重要的信息。
媒體
艾倫·阿特里奇
企業傳播高級副總裁
aattridge@vir.bio
投資者
理查德·萊普克
投資者關係高級董事
rlepke@vir.bio
資料來源:Vir 生物技術有限公司